Membrane transporters in drug development and as determinants of precision medicine

被引:22
|
作者
Galetin, Aleksandra [1 ]
Brouwer, Kim L. R. [2 ]
Tweedie, Donald [3 ]
Yoshida, Kenta [3 ]
Sjostedt, Noora [4 ]
Aleksunes, Lauren [5 ]
Chu, Xiaoyan [6 ]
Evers, Raymond [7 ]
Hafey, Michael J. [6 ]
Lai, Yurong [8 ]
Matsson, Par [9 ]
Riselli, Andrew [10 ]
Shen, Hong [11 ]
Sparreboom, Alex [12 ]
Varma, Manthena V. S. [13 ]
Yang, Jia [10 ]
Yang, Xinning [14 ]
Yee, Sook Wah [10 ]
Zamek-Gliszczynski, Maciej J. [15 ]
Zhang, Lei [16 ]
Giacomini, Kathleen M. [10 ]
机构
[1] Univ Manchester, Ctr Appl Pharmacokinet Res, Sch Hlth Sci, Manchester, England
[2] Univ North Carolina Chapel Hill, UNC Eshelman Sch Pharm, Div Pharmacotherapy & Expt Therapeut, Chapel Hill, NC USA
[3] Clin Pharmacol, Genentech Res & Early Dev, South San Francisco, CA USA
[4] Univ Helsinki, Fac Pharm, Div Pharmaceut Biosci, Helsinki, Finland
[5] Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmacol & Toxicol, Piscataway, NJ USA
[6] Merck & Co Inc, Dept Pharmacokinet Dynam Metab & Bioanalyt, Rahway, NJ USA
[7] Preclin Sci & Translat Safety, Johnson & Johnson, Janssen Pharmaceut, Spring House, PA USA
[8] Gilead Sci Inc, Drug Metab, Foster City, CA USA
[9] Univ Gothenburg, Sahlgrenska Acad, Dept Pharmacol, Gothenburg, Sweden
[10] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA
[11] Bristol Myers Squibb Res & Dev, Dept Drug Metab & Pharmacokinet, Princeton, NJ USA
[12] Ohio State Univ, Coll Pharm, Div Pharmaceut & Pharmacol, Columbus, OH USA
[13] Pfizer Inc, Pharmacokinet Dynam & Metab, Med Design, Worldwide R&D, Groton, CT USA
[14] US FDA, Ctr Drug Evaluat & Res, Off Clin Pharmacol, Silver Spring, MD USA
[15] Drug Metab & PK, GlaxoSmithKline, Collegeville, PA USA
[16] US FDA, Off Res & Stand, Off Gener Drugs, Ctr Drug Evaluat & Res CDER, Silver Spring, MD USA
基金
美国国家卫生研究院;
关键词
MDCK CELL-LINE; IN-VITRO; ENDOGENOUS BIOMARKERS; METABOLIZING-ENZYMES; EFFLUX TRANSPORTERS; P-GLYCOPROTEIN; HEPATIC-UPTAKE; QUANTITATIVE PROTEOMICS; SIMVASTATIN ACID; UPTAKE CLEARANCE;
D O I
10.1038/s41573-023-00877-1
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The effect of membrane transporters on drug disposition, efficacy and safety is now well recognized. Since the initial publication from the International Transporter Consortium, significant progress has been made in understanding the roles and functions of transporters, as well as in the development of tools and models to assess and predict transporter-mediated activity, toxicity and drug-drug interactions (DDIs). Notable advances include an increased understanding of the effects of intrinsic and extrinsic factors on transporter activity, the application of physiologically based pharmacokinetic modelling in predicting transporter-mediated drug disposition, the identification of endogenous biomarkers to assess transporter-mediated DDIs and the determination of the cryogenic electron microscopy structures of SLC and ABC transporters. This article provides an overview of these key developments, highlighting unanswered questions, regulatory considerations and future directions. Significant progress has been made in understanding the influence of membrane transporters in drug disposition and response. Here, the International Transporter Consortium provides an update on the current status of membrane transporters in drug development and regulatory requirements, discusses recent scientific advances in the field and highlights future directions and unanswered questions.
引用
收藏
页码:255 / 280
页数:26
相关论文
共 50 条
  • [21] Membrane transporters in drug disposition
    You, Guofeng
    PHARMACEUTICAL RESEARCH, 2008, 25 (02) : 441 - 443
  • [22] Membrane Transporters in Drug Disposition
    Kathleen M. Giacomini
    Journal of Pharmacokinetics and Biopharmaceutics, 1997, 25 : 731 - 741
  • [23] Membrane transporters in drug disposition
    Giacomini, KM
    JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1997, 25 (06): : 731 - 741
  • [24] Membrane transporters in drug discovery and development: A new mechanistic ADME era
    Ware, Joseph A.
    MOLECULAR PHARMACEUTICS, 2006, 3 (01) : 1 - 2
  • [25] Use of big data in drug development for precision medicine: an update
    Qian, Tongqi
    Zhu, Shijia
    Hoshida, Yujin
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2019, 4 (03): : 189 - 200
  • [26] Impact of Precision Medicine on Efficiencies of Novel Drug Development in Cancer
    Sarvas, Holly
    Carlisle, Benjamin
    Dolter, Samantha
    Vinarov, Esther
    Kimmelman, Jonathan
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2020, 112 (08): : 859 - 862
  • [27] Advances in the development of chordoma models for drug discovery and precision medicine
    Walker, Robert L.
    Hornicek, Francis J.
    Duan, Zhenfeng
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2022, 1877 (06):
  • [28] Lack of standardisation of ANA and implications for drug development and precision medicine
    Mahler, Michael
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 (05) : E33 - +
  • [29] THE EGGSHELL MEMBRANE: APPLICATIONS IN REGENERATIVE MEDICINE AND DRUG DEVELOPMENT
    Mensah, Rosemond A.
    Salim, Kawther
    Jo, Seung-Bin
    Kim, Hoon
    Park, Sung-Min
    Patel, Kapil D.
    Cho, Kyong Jin
    Sidney, Laura E.
    Alves-Lima, Decio
    Lin, Hungyen
    Nandin-Erdene, Mandakhbayar
    Lee, Jung-Hwan
    Kim, Hae-Won
    Chau, David Y.
    TISSUE ENGINEERING PART A, 2022, 28 : S235 - S235
  • [30] Organoids: development and applications in disease models, drug discovery, precision medicine, and regenerative medicine
    Yao, Qigu
    Cheng, Sheng
    Pan, Qiaoling
    Yu, Jiong
    Cao, Guoqiang
    Li, Lanjuan
    Cao, Hongcui
    MEDCOMM, 2024, 5 (10):